Finally, it should be emphasized that the modern strategies of ex vivo gene replacement therapy (already reached the stage of clinical trials) and ex vivo gene editing (still at the stage of preclinical studies) allow one to achieve a high level of correction of the COL7A1 mutation that is the main cause of RDEB. Here, COL7A1 is linked to recessive dystrophic epidermolysis bullosa.